Enanta Pharmaceuticals patents new 17-β-HSD 13 inhibitors

Nov. 20, 2023

Enanta Pharmaceuticals Inc. has disclosed 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17-β-HSD 13) inhibitors reported to be useful for diseases of the liver.

BioWorld Science Gastrointestinal Patents

Today's news in brief

BioWorld

BioWorld briefs for Dec. 4, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 4, 2025.

Illustration of chromosome unraveling down to the DNA

First phase of synthetic human genome project successfully completes

BioWorld Science

The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

Mesothelin is biomarker, potential target in arthritic bone damage

BioWorld Science

In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...